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Abstract Epilepsy is a common neurological disorder char-
acterized by recurrent seizures. These seizures are due to
abnormal excessive and synchronous neuronal activity in the
brain caused by a disruption of the delicate balance between
excitation and inhibition. Neuropeptides can contribute to such
misbalance by modulating the effect of classical excitatory and
inhibitory neurotransmitters. In this review, we discuss 21
different neuropeptides that have been linked to seizure disor-
ders. These neuropeptides show an aberrant expression and/or
release in animal seizure models and/or epilepsy patients.
Many of these endogenous peptides, like adrenocorticotropic
hormone, angiotensin, cholecystokinin, cortistatin, dynorphin,
galanin, ghrelin, neuropeptide Y, neurotensin, somatostatin,
and thyrotropin-releasing hormone, are able to suppress sei-
zures in the brain. Other neuropeptides, such as arginine-
vasopressine peptide, corticotropin-releasing hormone, en-
kephalin, β-endorphin, pituitary adenylate cyclase-activating
polypeptide, and tachykinins have proconvulsive properties.
For oxytocin and melanin-concentrating hormone both pro-
and anticonvulsive effects have been reported, and this seems
to be dose or time dependent. All these neuropeptides and their
receptors are interesting targets for the development of new
antiepileptic drugs. Other neuropeptides such as nesfatin-1 and
vasoactive intestinal peptide have been less studied in this
field; however, as nesfatin-1 levels change over the course of
epilepsy, this can be considered as an interesting marker to
diagnose patients who have suffered a recent epileptic seizure.
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Introduction
Epilepsy is one of the most common neurological disorders,
affecting about 70 million people worldwide [1]. In some
cases, epilepsy has a genetic etiology, while in other cases
precipitating events such as head trauma, inflammation, stroke,
tumors, or prolonged febrile seizures during childhood lead to
the development of epilepsy. The fundamental characteristic of
epilepsy is the occurrence of recurrent, unprovoked seizures.
These seizures are a result of excessive electrical discharges in
a group of neurons that fire with a synchrony that never occurs
during normal behavior. They are caused by a disruption of the
delicate balance between inhibition and excitation in the brain.
On the neurotransmitter level, two major players contribute to
such misbalance: the inhibitory transmitter GABA and the
excitatory transmitter glutamate. Neuropeptides are powerful
modulators of these classical neurotransmitters, either by mod-
ifying their release or by regulating their effects at the receptor
level, and can hence influence the balance between inhibition
and excitation. Neuropeptides also modulate monoaminergic
transmission, such as dopamine and serotonin, and can thereby
also alter brain excitability. Furthermore, as they are stored in
large dense core granules, neuropeptides are likely released
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during sustained high-frequency activity (5–40 Hz), such as
that occurring during epileptiform seizures.
In the past years, numerous neuropeptides have been linked
to epilepsy [2, 3]. Aberrant neuropeptide levels were found in
plasma, cerebrospinal fluid (CSF) and resected tissues from
epilepsy patients and in different animal seizure models
(Table 1).1 Some of these neuropeptides have been implicat-
ed in the regulation of seizure susceptibility. In fact, many
endogenous neuropeptides display anticonvulsive effects in
animal models of epilepsy. Hence, these neuropeptides and
their receptors are attractive targets for the development of
new antiepileptic drugs (AEDs). Other neuropeptides show
proconvulsive effects, which makes their receptors also inter-
esting targets for suppressing seizures using, e.g., receptor-
specific antagonists. AEDs suppress seizure activity and
thereby greatly improve the quality of life of epilepsy patients.
Unfortunately, at present, only two thirds of patients achieve
good seizure control under pharmacological treatment [1].
Therefore, new drug targets are needed.
Currently, only one neuropeptide is being used as a therapy
for epilepsy. Adrenocorticotropic hormone (ACTH) is the
most commonly used treatment for infantile spasms [4].
Thyrotropin-releasing hormone (TRH) also shows promising
results in clinical studies for the treatment of infantile spasms
[5–7]. For other neuropeptides, data are restricted to preclinical
evidence. In this review, we discuss 21 different neuropeptides
that have been linked to seizure disorders. We describe how
seizures influence neuropeptide levels and how certain neuro-
peptides can modulate seizures (summarized in Table 2). This




Neuropeptide Y (NPY) is one of the most studied neuropep-
tides in epilepsy. We here summarize the major findings and
refer to other reviews for further details. NPY is abundantly
expressed in GABAergic interneurons of the mammalian
central nervous system (CNS), including in the hippocampus.
NPY can signal through five different receptors Y1-Y5, but
predominantly acts by binding to Y1, Y2, and Y5. During
seizures NPY is strongly upregulated and the release of NPY
is increased in the regions of the seizure, as shown in several
animal models as well as in epilepsy patients [8–11]. In
patients with mesial temporal lobe sclerosis, a cell-specific
loss of NPY-containing interneurons in the hippocampus was
observed [12]. Chronic seizure activity also alters NPY
1 Table 1 gives an overview of all animal seizure models referred to in this
review.
Table 1 Overview of animal models referred to in this review [216]
Chemically induced seizures
GABA-related drugs: pentylenetetrazol (PTZ), bicuculline
and picrotoxin models
These GABAA receptor antagonists can serve as models for acute
seizures. Low doses induce absence seizures while moderate doses
induce clonic seizures and high doses cause tonic–clonic seizures.
These seizure episodes generally resolve in relatively short time.
However, continuously high doses may lead to generalized status
epilepticus and eventually death.
Glycine-related drugs: strychnine model
This glycine receptor blocker can serve as a model of therapy-
resistant seizures arising from the lower brainstem and spinal cord.
Glutamate-related drugs: kainic acid model
This glutamate receptor agonist can serve as a model for temporal
lobe epilepsy. A single large dose or repeated lower doses, injected
systemically or intracerebrally, induce severe acute seizures (acute
phase) with subsequent status epilepticus, which is followed by a
quiescent period of usually several weeks (silent phase). This latent
period is followed by the development of spontaneous recurrent
seizures (chronic phase) and brain damage.
Acetylcholine-related drugs: pilocarpine model
This cholinergic agonist can serve as a model for temporal lobe
epilepsy. Large dosages, injected systemically or intracerebrally,
induce severe acute seizures (acute phase) with subsequent status
epilepticus which is followed by a quiescent period of usually
several weeks (silent phase). This latent period is followed by the
development of spontaneous recurrent seizures (chronic phase).
Chemical kindling models
Subthreshold doses of convulsant drugs, such as pentylenetetrazol,
are repeatedly injected and lead to generalized seizures. Chemical




Repetitive, focal application of initially subconvulsive electrical
stimulation can ultimately result in generalized seizures. Kindling
may also lead to the appearance of spontaneous seizures and can
be used as a model for temporal lobe epilepsy. Stimulation can be
performed in the amygdala, hippocampus, piriform cortex,
perirhinal cortex or frontal cortex and all show different features.
6 Hz corneal stimulation model
In this electroshockmodel, a 6-Hz electrical stimulus is administered
to the cornea for a prolonged period (typically 3 seconds). Corneal
stimulation presents a model for partial seizures.
Hyperthermia induced seizures
Febrile seizure model
In this model, seizures are evoked by hyperthermia, via mechanisms
comparable to those of fever. The body temperature is increased in
immature animals at an age when brain development corresponds
to that of human infants when they are most susceptible to febrile
seizures. The seizures are limbic in semiology and involve the
hippocampal formation. About one third of the animals develop
temporal lobe epilepsy later in life.
Sensory-evoked seizures (in genetic animal models)
Audiogenic model
In the audiogenic seizure model, animals display generalized clonic
or tonic–clonic seizure activity in response to intense sound
stimulation. A few strains of rats [theWistar audiogenic rat (WAR)]
and mice [dilute brown non-Agouti (DBA)] are genetically
susceptible to audiogenic seizures.
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receptor expression, with an upregulation of Y2 and a down-
regulation of Y1 receptors [13–15].
NPY acts as an endogenous anticonvulsant, known to
prevent seizures by increasing the seizure threshold. The
anticonvulsant effect of NPY has been demonstrated in dif-
ferent models of acquired and genetic epilepsy. It is also
supported by studies using transgenic animals, showing that
genetically modified rats overexpressing the NPY gene are
less susceptible to seizures while deletion of the NPY gene
results in increased susceptibility to seizures [16, 17]. To
assess the therapeutic potential of NPY, a long-lasting NPY
over-expression was achieved in the rat hippocampus by local
application of recombinant adeno-associated virus (AAV)
vectors. This resulted in reduced generalization of seizures,
delayed kindling epileptogenesis, and strong reduction of
chronic spontaneous seizures [3, 18, 19].
NPYenhances inhibitory neurotransmission, and dampens
excitatory neurotransmission [20]. Studies investigating
which NPY receptor subtypes are most important inmediating
its anticonvulsant actions give conflicting results [21]. Y2 is
mainly expressed presynaptically, where NPY inhibits the
presynaptic release of the excitatory transmitter glutamate
and can thereby reduce hyperexcitability [22]. Also Y5 recep-
tor activation has been implicated in decreasing glutamate
release in the hippocampus and in reducing seizures [23]. In
the hippocampus, NPY does not seem to affect GABAergic
neurotransmission onto pyramidal neurons. In the neocortex,
however, NPY can induce a long-lasting increase of
GABAergic neurotransmission on pyramidal neurons. This
could be mediated through the predominantly postsynaptical-
ly located Y1 receptors and would also decrease excitability in
cortical circuits and thereby contribute to the powerful anti-
convulsant effect of NPY in the neocortex [20, 24]. Yet, the
role of Y1 is ambiguous as Y1 receptors have been reported to
mediate pro- as well as anticonvulsant effects. Administration
of anticonvulsant doses of NPY also results in an increase of
hippocampal dopamine, via activation of sigma 1 receptors
[25]. This could contribute to the anticonvulsant effect of
NPY. Dopamine can both promote or inhibit hippocampal
excitability and seizure activity depending on the receptor,
respectivelyD1 orD2, that is activated, however, the net effect
of increased hippocampal dopamine is an attenuation of lim-
bic seizures via D2 receptor stimulation [26]. For more details
on the mechanisms and receptors involved in the anticonvul-
sant actions of NPY we refer to other reviews [2, 27, 28].
NPY may also play a role in the mechanisms by which
experimental febrile seizures (FS) protect the hippocampus
against the occurrence of additional seizures [29]. FS are
elicited by a high body temperature and affect 2-3 % of the
children between 3 months and 5 years. Short or simple FS,
also referred to as typical FS, are considered benign. However,
complex FS, i.e. seizures that persist for more than 15 minutes
or recurrent seizures within the same febrile illness,
considerably increase the risk for the development of temporal
lobe epilepsy (TLE) later in life [30, 31]. In 80–90 % of
human FS, only a single seizure occurs within a febrile epi-
sode. A single hyperthermic seizure leads to a significant
elevation of temperatures required to elicit a second (or third)
seizure. After an experimental FS, NPY expression is in-
creased in the dentate gyrus, CA1 and CA3 region of the
hippocampus. This increase in NPY expression might be
important for the protection against additional seizures as the
protective effect is abolished by a Y2 antagonist. Hence, if
recurrent seizures do occur within a febrile episode, they may
indicate that the underlying anti-excitatory processes mediated
by NPY are not normal. One study shows that children with
complex FS have significantly lower plasma NPY levels than
children with typical FS or controls, suggesting that patients
with inadequate NPY inhibitory activity are more susceptible
to complex FS [32]. Another study, however, shows no cor-
relation between plasma NPY levels and FS [33].
The upregulation of NPY and NPY receptor expression in
the dentate gyrus after seizures may also be important in
seizure-induced neurogenesis, as mice lacking NPY or the
Y1 receptor show a reduced basal and seizure-induced prolif-
eration in the dentate gyrus [34]. Seizures increase adult
neurogenesis in the subventricular and subgranular zones,
however, the role of this increased neurogenesis in seizure
generation and epileptogenesis remains elusive [35].
In summary, changes in the NPY system induced by sei-
zures may represent an endogenous adaptive mechanism
aimed at counteracting hyperexcitability underlying epileptic
activity.
Galanin
The neuropeptide galanin and its cognate receptors (GAL 1-3)
are widely distributed in the mammalian CNS. Galanin is a
potent endogenous anticonvulsive peptide. Several reviews
discuss the role of galanin and galanin receptors in epilepsy
[3, 36, 37]. We will here summarize some important findings.
Seizures lead to dramatic changes in galanin expression. Sta-
tus epilepticus leads to the profound depletion of galanin from
the hippocampus, which may contribute to the maintenance of
seizure activity [38].
Galanin receptor agonists exhibit anticonvulsant effects
after intrahippocampal administration in both acute and chron-
ic animal models of epilepsy [38, 39]. A functional disruption
of the galanin gene leads to a higher seizure susceptibility.
Galanin KOmice show increased propensity to develop status
epilepticus after perforant path stimulation or systemic kainic
acid, as well as greater severity of pentylenetetrazol (PTZ)-
induced convulsions [40]. Overexpression of the galanin gene
in brainstem and entorhinal cortex hinders seizure induction in
all three models [40]. Galanin also seems to be effective in
preventing hyperthermia-induced seizures [41].
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Galanin can act on three receptors GAL 1-3, but exerts
anticonvulsant effects through the receptors GAL1 and
GAL2, which are both expressed in the hippocampus, but
with distinct downstream signaling cascades. While GAL1,
expressed in CA1, is involved in the initiation phase, GAL2,
abundant in the dentate gyrus, is implicated in the mainte-
nance phase and the severity of epileptic seizures. GAL1
receptor KO mice develop spontaneous seizures [42, 43]. In
the dentate gyrus, galanin, acting through GAL2, inhibits
seizures, promotes viability of hilar interneurons and stimu-
lates seizures-induced neurogenesis [44]. Seizure activity does
however not significantly alter the expression of hippocampal
galanin receptors. In the hippocampus, galanin most likely
exerts its effect via presynaptic inhibition of excitatory gluta-
matergic neurotransmission. Galanin inhibits depolarization-
induced glutamate release from rat hippocampal slices [45].
Hippocampal slices from galanin KOmice release significant-
ly more glutamate than slices from wild type mice, whereas
slices from galanin overexpression mice do not show gluta-
mate release to the same depolarization challenge [40]. Acti-
vation of the galanin receptor might lead to hyperpolarization
of the presynaptic cells by opening ATP-dependent K+-chan-
nels and closing voltage-dependent Ca2+-channels and hence
impeding glutamate release and the progression of seizures
[46, 47]. Galanin is also capable of modulating seizure activity
through interaction with serotonin. The major effect of sero-
tonin in the hippocampus is anticonvulsant. Galanin receptors
are present on serotonergic neurons in the dorsal raphe, which
project to the hippocampus. Activation of the GAL1 receptor
in the dorsal raphe inhibits serotonin release in the hippocam-
pus, which increases the severity of limbic seizures. On the
other hand, activation of GAL2 receptors in the dorsal raphe
increases serotonin release, which translates in the inhibition
of limbic seizures [48]. Since GAL1 is far more abundant in
the dorsal raphe than GAL2, the net effect of galanin in the
dorsal raphe is most likely GAL1 dependent. The different
effects of GAL1 and GAL2 in the dorsal raphe might have
important implications for the application of GAL receptor
subtype specific agonists. The beneficial effect of GAL1
activation in the hippocampus might be mitigated by an
undesirable inhibition of serotonergic innervations. GAL2
activation, however, has anticonvulsant effects both in the
hippocampus and in the dorsal raphe.
Galanin receptors are considered as an interesting target for
anticonvulsive therapy. Several synthetic agonists of galanin
receptors with optimized bioavailability were shown to inhibit
experimental seizures upon systemic administration in differ-
ent animal models (reviewed by [36]). Galanin is also consid-
ered as an important target for the future progression of
antiepileptic gene therapy. AAV vector-mediated expression
and constitutive secretion of galanin has proven to significant-
ly attenuate limbic seizure activity and prevent seizure-
induced cell death in animal models [49, 50].
Ghrelin
Ghrelin exists in two forms: desacylated ghrelin (DAG) and
acylated ghrelin (AG, also referred to as ghrelin). After secre-
tion, ghrelin is rapidly desacylated so that DAG is the main
circulating peptide. Ghrelin was long supposed to be the only
biologically active form, as acylation is essential for binding
to the growth hormone secretagogue receptor type 1a
(GHSR1a). Recently, it has been shown that DAG also has
biological actions. In the CNS, the main site of ghrelin syn-
thesis is the hypothalamus [51]. The ghrelin receptor GHSR1a
is widely expressed; both peripherally and centrally, including
in seizure-prone regions such as the hippocampus [52]. Ghrel-
in may play a role in epilepsy, but some of the current data are
conflicting. For an extensive review, we refer to [53]. In a
PTZ-animal model, ghrelin blood levels significantly decrease
after seizures [54]. It is possible that this reduction is due to
somatostatin, released during PTZ-induced seizures, as so-
matostatin is known to reduce the systemic plasma concentra-
tion of ghrelin. In addition, somatostatin decreases ghrelin O-
acyl transferase expression, an enzyme that catalyzes the
acylation of ghrelin [55]. Ghrelin reduction might also be
due to the release of leptin during PTZ-induced seizures, since
ghrelin is negatively regulated by leptin [56, 57]. Clinical
studies on the relationship between ghrelin and epilepsy are
contradictory, as some of them show increased ghrelin levels
and others no changes or even a decrease. As summarized in
the review of Portelli et al. [53], too many variables are present
among these studies; however, the general consensus is that
ghrelin levels have the tendency to decrease following epilep-
tic episodes.
Animal models have demonstrated that ghrelin has an
anticonvulsant action. Exogenous ghrelin inhibits the devel-
opment and severity of PTZ-induced seizures in rats [58].
Another study shows that ghrelin is unable to prevent seizures
induced by kainic acid or pilocarpine [59]. However, DAG is
able to prevent status epilepticus in 60 % of pilocarpine-
treated rats and significantly delay the onset of status epilep-
ticus in kainic acid-treated rats [59]. Given the limited number
of animals used in these studies, further research is needed to
determine whether ghrelin is protective against seizures and
against which type of epileptic seizures.
Studying the role of the ghrelin receptor GHSR1a in animal
models of epilepsy gave some interesting results. Inactivation
of GHSR1a by deletion, inverse agonism, or desensitization
led to the attenuation of limbic seizures [60]. This indicates
that both agonists and inverse agonists for GHSR1a are capa-
ble of exerting anticonvulsant effects. The GHSR1a signals
with approximately 50 % maximal activity in the absence of
its peptide ligands, rendering it one of the few highly consti-
tutively active G-protein coupled receptors currently known.
Ghrelin requires GHSR1a for its anticonvulsant effect, and it
is desensitization and not activation of GHSR1a that is
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necessary to attenuate limbic seizures in vivo [60]. It has been
demonstrated that ghrelin neurons have excitatory synaptic
junctions on the axons of NPY neurons in the arcuate nucleus
of the hypothalamus. Ghrelin increases the firing of NPY/
agouti-related peptide (AgRP) neurons, which is postulated
to increase the rate of secretion of GABA and maybe also
NPY and AgRP [61]. Both NPY and GABA are known to
have inhibitory effects on seizures. Impairment of GABA-
mediated inhibitory circuits has been implicated in different
forms of epilepsy in experimental animal models and in
human studies. However, further research is needed as these
ghrelin-NPY/GABA interactions were described only in the
hypothalamic circuitry and not in cortical or limbic brain
regions, which are mainly involved in the generation of sei-
zures. In fact, in the hippocampus ghrelin did not alter extra-
cellular GABA levels when administered intrahippocampally,
indicating that the anticonvulsant action of ghrelin against
limbic seizures does not involve GABA alterations in the
hippocampus [60].
Ghrelin also plays a neuroprotective role and stimulates
proliferation and differentiation of adult hippocampal neuro-
nal progenitor cells [62]. Therefore, it might play a role in
reducing neuronal cell loss after hippocampal damage induced
by epilepsy. In this respect, it has been shown that ghrelin
significantly reduces neuronal death by pilocarpine- and
kainic acid-induced seizures [63, 64]. Ghrelin most likely
exerts this neuroprotective effect by promoting the PI3K/Akt
signaling pathway and inhibiting the mitochondrial apoptosis
pathway. This appears to be mediated through the activation
of GHSR1a, as a specific antagonist of GHSR1a blocks the
protective effect [65].
Somatostatin
Somatostatin has been implicated as playing a prominent role
in epilepsy (reviewed by [66, 67]). Somatostatin exists in two
active forms, i.e., somatostatin-14, having 14 amino acids and
somatostatin-28, having 28 amino acids. Both are produced
by alternative cleavage of a single proprotein. Somatostatin-
14 is dominant in the brain. It is primarily known as the
hypothalamic-inhibiting hormone that regulates the release
of growth hormone from the anterior pituitary. Somatostatin
is, however, widely distributed throughout the CNS. In most
brain regions, its function remains unclear. Somatostatin can
act on five different receptors, SST-1–5. SST-1–4 are
expressed in the hippocampus, and SST-2–4 likely participate
in the anticonvulsant action of the somatostatin peptide. SST-1
acts as an inhibitory autoreceptor and is most likely not
involved in the anticonvulsant effects of somatostatin [68].
In the hippocampus, the somatostatin peptide is mostly
expressed in GABAergic interneurons in the hilus. These
somatostatin interneurons represent about 16 % of the total
GABAergic neurons in the dentate region. They also express
mGluR1 and substance P receptors and about 30 % coexpress
NPY. These interneurons project to the outer molecular layer
onto dendrites of dentate granule cells, adjacent to perforant
path synapses, and inhibit these granule cells. Somatostatin
receptors are mainly located on granule cells. Hence, these
somatostatin interneurons could modulate excitatory input
that comes from the entorhinal cortex via the perforant path
into the hippocampus. Their dendrites remain in the hilus,
where they receive input from mossy fiber collaterals of
dentate granule cells. This circuitry provides inhibitory feed-
back control on dentate granule cells [67]. After repetitively
induced seizures, the density of somatostatin interneurons in
the hilus of the dentate gyrus significantly decreases. This is
shown in several animal models of TLE and is confirmed in
TLE patients [12, 69, 70]. In fact, the loss of somatostatin
interneurons is considered as a hallmark of epileptic hippo-
campus. It is still unclear, however, why somatostatin inter-
neurons are so vulnerable to seizures-induced death and how
exactly this neuronal loss contributes to epileptogenesis or
post-seizure hyperexcitability. According to one hypothesis,
the loss of hilar interneurons leads to reduced GABAergic
inhibition of dentate granule cells, which contributes to their
hyperexcitability. This was shown after electrical stimulation-
induced, self-sustaining status epilepticus (SSSE) in rats [71].
In contrast, other studies report that the loss of interneurons is
not accompanied by an equivalent decrease in inhibition.
Compensatory functional changes are expected to increase
the inhibitory output of surviving somatostatin interneurons
and in part compensate for interneuronal loss in the epilepto-
genic hippocampus [72]. Surviving hilar somatostatin inter-
neurons enlarge, extend dendrites, receive increased excitato-
ry input on distal dendrites, sprout axon collaterals in the
molecular layer, and form new synapses with granule cells
[73]. This way the surviving hilar interneurons inhibit more
granule cells and compensate for the loss of vulnerable inter-
neurons. Hilar neurons containing NPYare also susceptible to
excitotoxic damage in some epileptic models, but their loss is
less pronounced than the larger group of somatostatin-
containing neurons. As NPYand somatostatin are colocalized
in some hilar neurons, these might reflect the same neuronal
population. Prior to the death of somatostatin interneurons,
somatostatin expression is increased by seizures. The somato-
statin gene contains a prototypical cAMP regulatory element
site that confers activity dependence to the gene, meaning that
it is turned onwhen neuronal activity is high. This explains the
high somatostatin messenger RNA (mRNA) and peptide
levels seen in seizure models. Somatostatin expression is
increased in the hippocampus and cortex just before and im-
mediately after ultra-red-induced convulsions in rat [74]. Also
after hippocampal kindling, mRNA expression and peptide
levels are increased in the hippocampus [75], and after kainic
acid-induced seizures, ectopic expression of somatostatin in
dentate granule cells and pyramidal cells was demonstrated
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[76]. Somatostatin also shows activity-dependent release dur-
ing seizures. In an in vivo hippocampal microdialysis study
and in ex vivo hippocampal slices, an increase in both basal
and K+-stimulated release was reported after kindling [77, 78].
Children with FS also have higher somatostatin titers in CSF
compared to age-matched controls [79]. The somatostatin level
is highest the first hours after the seizure. In addition, children
with epilepsy show significantly higher somatostatin levels in
CSF. This points to an increased somatostatin release from
overactive neurons and/or leakage of somatostatin from dam-
aged or anoxic neurons. The increased release of somatostatin
following seizures is likely protective. Somatostatin receptors
SST-2–4 in the dentate gyrus are mainly located on granule
cells, which are largely spared from seizure-induced neuronal
death. However, after kindling, somatostatin receptors appear
to be downregulated probably by desensitization due to the
high somatostatin levels [80].
Exogenous somatostatin and agonists of the SST-2 receptor
reduce the severity, total number, and duration of seizures in
rats, while somatostatin antiserum has proepileptic effects
[81–84]. Studying the receptors that mediate the anticonvul-
sant actions of somatostatin, species-specific differences were
found. In rats, the anticonvulsant effects seem to be mostly
mediated by SST-2. Somatostatin as well as SST-2 agonists
can prevent or attenuate pilocarpine-induced status epilepti-
cus. At the Schaffer collateral-CA1 synapses, somatostatin
suppresses presynaptic glutamate release, and this effect is
mediated by SST-2 [85, 86]. SST-3 and SST-4 also show
anticonvulsive properties in the rat hippocampus. However,
SST-2 antagonism prevents the SST-3 or SST-4 mediated
anticonvulsant effects, suggesting a functional crosstalk be-
tween these receptors [87]. In mice, SST-4 mediates the anti-
convulsant effects, while SST-2 does not seem to play a role in
the modulation of seizure susceptibility [88, 89].
Cortistatin
Cortistatin shares strong sequence similarity with somatostatin
(11 out of 14 residues for rat and mouse, while the human
peptide is extended by three residues), but is derived from a
different gene. It binds to the same receptors, SST-1–5, how-
ever with lower affinity than somatostatin itself. In the cortex,
cortistatin and somatostatin are expressed in partially overlap-
ping populations of interneurons, while within the hippocam-
pus, they seem to be predominantly colocalized in inhibitory
GABAergic interneurons. Cortistatin and somatostatin are
most likely regulated by different stimuli, as their precursor
genes contain binding motifs for different transcriptional regu-
latory factors, and, unlike somatostatin, cortistatin is not signif-
icantly upregulated by increases in neural activity induced by
kainic acid in adult rats [90]. In immature rats, however,
cortistatin is highly expressed in the hippocampus and expres-
sion further increases after kainic acid-induced seizures [91].
Cortistatin exhibits an anticonvulsive effect against kainic
acid-induced seizures in rats. Furthermore, cortistatin shows a
neuroprotective role, as it markedly reduces the kainic acid-
induced cell loss of cortical and hippocampal neurons [92].
This is in line with its (increased) expression in the immature
brain, which shows a relative resistance to seizure-induced
neuronal injury.
Angiotensins
Besides their crucial role in cardiovascular regulation, angio-
tensin (Ang) peptides have been implicated in the regulation
of seizure susceptibility. Five peptides, Ang I–II–III–IV and
Ang 1–7, are generated from the precursor protein
angiotensinogen by consecutive enzymatic steps. Ang I has
little or no known biological activity. Ang II and III act
through two receptors, AT1 and AT2. Ang 1–7 mainly acts
via the Mas receptor and is thought to counterbalance most of
the Ang II effects. Ang IVexerts its effects through inhibition
of insulin-regulated aminopeptidase (IRAP), also referred to
as AT4. Patients with TLE show an increased expression of
the AT1 and AT2 receptors in the cortex and hippocampus
[93]. In an audiogenic animal model of epilepsy, besides AT1,
also angiotensin-converting enzyme (ACE) is upregulated in
the brain following repetitive seizures [94]. ACE is responsi-
ble for the conversion of Ang I into Ang II. In genetic
audiogenic models of epilepsy, Wistar audiogenic rats or
DBA/2 mice treated with an AT1 blocker or ACE inhibitors
show a significant decrease in seizure severity [94, 95]. In
contrast, in a pilocarpine model, ACE expression was reduced
in all phases [96]. Here, it was proposed that angiotensinogen
may be directly cleaved to Ang II by the enzyme tonin, which
showed increased expression in all phases. In the same pilo-
carpine model, an increased concentration of Ang II and the
AT1 receptor was seen in the hippocampus of rats in the
chronic phase, while Ang II levels and AT1 expression were
very low in the acute and silent phase. The conversion of Ang
II to Ang 1–7 decreased during all phases. AT2 receptor
expression, on the other hand, was increased in the hippocam-
pus in the acute and silent phase and showed no alteration in
the chronic phase [96].
The peptides Ang II, Ang III, and Ang IV show anticon-
vulsive effects in several animal models. Intracerebroventric-
ular administration of Ang II increases the threshold of PTZ-,
bicuculline-, and picrotoxin-induced seizures in mice and
decreases the intensity of seizures induced by systemic ad-
ministration of PTZ. Furthermore, Ang II, Ang III, and Ang
IV protect against clonic convulsions in PTZ kindled mice
[97–102]. The effect of Ang II and III is most likely mediated
by the AT1 receptor. It was previously reported that AT1
receptors, located pre- and postsynaptically, are capable of
influencing both inhibitory and excitatory neurotransmission
[103]. The anticonvulsive effect of Ang IV may be mediated
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through inhibition of IRAP. Ang IV is a potent and competi-
tive IRAP inhibitor. The involvement of IRAP in seizure
generation is stressed by the fact that IRAP knockout mice
are less sensitive to the development of PTZ-induced seizures
[104]. IRAP is known to cleave a number of bioactive neuro-
peptides, such as oxytocin, arginine-vasopressine peptide,
substance P, neurokinin A, met-enkephalin, dynorphin A,
cholecystokinin-8, and somatostatin-14, all peptides which
have been implicated in seizure generation. IRAP can alter
the level of these circulating peptides and hence influence
seizure development. In this respect, it was shown that the
ability of Ang IV to inhibit pilocarpine-induced convulsions is
dependent on SST-2 receptor activation and thus is possibly
mediated via the inhibition of IRAP resulting in an elevated
concentration of somatostatin-14 in the brain [105]. Ang IV in
addition shows an antiepileptogenic effect as it is also able to
block the development of an epileptic-like state in mice.
The effect of Ang peptides on seizure susceptibility could
be regulated through their close interaction with different
neurotransmitter/neuromodulator systems such as dopamine,
GABA, and adenosine (reviewed in detail by [99]). Anatom-
ical, biochemical, and behavioral data point out that dopami-
nergic pathways play a role in Ang II-related effects. It was
shown that Ang II increases the threshold of PTZ-induced
seizures through a dopamine-related mechanism [106]. On the
other hand, Ang II also potentiates the inhibitory action of
GABA and GABAergic agonists on the PTZ seizure threshold
and seizure intensity [99]. The anticonvulsant effect of Ang III
and Ang IV and the antiepileptogenic effect of Ang IV in the
kindling model may be (partly) mediated by adenosine-
dependent mechanisms through activation of the adenosine
A1 receptor [97, 107]. Adenosine inhibits synaptic activity
and neurotransmitter release and is a potent anticonvulsant in
different seizure models.
Cholecystokinin
Cholecystokinin (CCK) was originally discovered in the gas-
trointestinal tract, but is also an abundant and widely distrib-
uted neuropeptide in the brain, with high levels in the hippo-
campus. Different molecular forms ranging in size from 4 to
83 amino acids have been identified (e.g., CCK-58, CCK-33,
and CCK-8), all derived from the same precursor
preprocholecystokinin. The sulfated octapeptide CCK-8 is
the predominant form in the brain. CCK has two different
receptors, CCK1 and CCK2. CCK2 is the dominant form in
the brain. CCK levels are significantly altered upon seizures.
In several models of TLE, hippocampal CCK immunoreac-
tivity is reduced, either indicating decreased expression, as in
the mossy fiber pathway, or potentially degeneration, as in
mossy cell and basket cell terminals [108, 109]. In a mouse
pilocarpine model of recurrent seizures, an increase in CCK
expression was shown in spiny neurons and glutamatergic
terminals, possibly originating from pyramidal cells that in-
nervate strata radiatum and oriens of CA1, while in other
layers of the hippocampus CCK expression was decreased
[110]. Also in TLE patients, CCK levels were 20 % lower in
the temporal cortex from which active epileptic spiking was
recorded in comparison to tissue samples, which were
electrographically free of epileptiform spikes [111].
CCK-8 has been demonstrated to have anticonvulsive
properties in animal models by delaying the seizure onset
and increasing the seizure threshold of convulsants such as
PTZ and picrotoxin [112, 113].
In normal conditions, CCK is postulated to be released
under strong, repetitive stimulation, activating predominantly
CCK2 receptors in the brain. There is evidence that activation
of CCK2 receptors in hippocampal interneurons and pyrami-
dal cells produces a depolarizing response by decreasing
potassium conductance. Accordingly, CCK can enhance
GABA as well as glutamate release in the hippocampus
[114, 115]. The subsequent effect depends on the cell types
and precise synapses involved. In mossy fiber axons, CCK is
codistributed with the opioid peptides enkephalin and
dynorphin. Recurrent seizure activity increases enkephalin
immunoreactivity and decreases CCK and dynorphin levels.
As enkephalin can induce limbic seizures when injected into
the hippocampus, while CCK has anticonvulsive properties,
one might speculate that the shift in CCK/enkephalin balance
in the mossy fiber system following seizures might underlie
future seizure susceptibility [108, 116, 117].
Neurotensin
Neurotensin is widely distributed in the CNS, with the highest
concentrations in the limbic system. There is considerable
evidence that this neuropeptide might act as a regulator of
neuronal excitability. There are three known neurotensin re-
ceptors. NTS1 and NTS2 are G-protein-coupled receptors,
while NTS3 is composed of a single transmembrane domain.
NTS1 and NTS2 are present on neurons in the basolateral
amygdala and hippocampus, which are known to be involved
in seizure activity. Neurotensin-like immunoreactivity is re-
duced in the frontal cortex and hippocampus of rats during and
after limbic seizures induced by systemic injection of kainic
acid [118]. These early decreases in peptide levels may result
from increased release and subsequent enzymatic inactivation
of the peptides during acute seizures. Neurotensin-like immu-
noreactivity normalizes in the hippocampus after the period of
acute convulsions, but remains decreased in the frontal cortex
up to 30 days. This late decrease in peptide levels could reflect
degeneration of neurotensin-containing neurons projecting
from limbic brain areas to the cortex. Meanwhile, neurotensin
levels increase in the striatum and substantia nigra, which
might be a consequence of strong activation of the dopamine
system in these areas, where neurotensin and dopamine show
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a close anatomical and functional relation [119]. Changes in
neurotensin levels seem to be seizure-type specific, as no
changes in peptide levels were shown in different brain re-
gions in kindling models [120]. This might be explained by
the fact that, in contrast to the kindling model, the kainic acid
model simulates status epilepticus that is associated with
hippocampal cell death.
Neurotensin and some glycosylated analogues exhibit
(sub)picomolar anticonvulsant potencies in a corneal stimula-
tion mouse model of epilepsy [121]. It is not known how
neurotensin receptors mediate the anticonvulsive properties
[122]. It might be related to the fact that neurotensin potenti-
ates GABAergic activity in the rat hippocampus CA1 region
[123]. Neurotensin analogues combining lipidization and
cationization show improved metabolic stability and CNS
bioactivity, resulting in enhanced antiseizure activity in the
corneal stimulation model following intraperitoneal adminis-
tration of the analogues [124].
Dynorphins
Dynorphins belong to the family of endorphins and act
through binding the opioid receptors (δ, μ, and κ). Most of
dynorphin’s effects are mediated by the κ-receptor.
Dynorphins are produced in different parts of the brain, in-
cluding the hypothalamus, hippocampus, midbrain, medulla,
pons, and spinal cord and have different physiological effects,
depending on their site of production. They can modulate pain
responses and maintain homeostasis through appetite control
and regulation of body temperature [125]. In amygdaloid
kindling and kainic acid models, dynorphin release is in-
creased, while expression in the hippocampus is reduced,
possibly as a consequence of depletion during the seizures
[117, 126–128]. Also after induction of status epilepticus, a
decrease in dynorphin-like immunoreactivity was observed in
the dentate gyrus and CA3 of the hippocampus [129]. In TLE
patients, however, a dynamic upregulation of prodynorphin
mRNA expression was seen in the dentate gyrus. Highest
transcript levels were seen postictally [130]. It was also shown
that opioid receptor binding increases in patients within the
first hours after a spontaneous seizure, suggesting an impor-
tant role of the opioid system in seizure control [131].
Κ-opioid receptor agonists can prevent both behavioral and
electroencephalographic measured seizures in different
models of epilepsy [132] and counteract the initiation and
maintenance of status epilepticus [129]. Prodynorphin knock-
out mice display a significantly reduced seizure threshold,
faster seizure onset and prolonged seizure activity in PTZ
and kainic acid models. This phenotype can be rescued by a
κ-receptor-specific agonist [133]. Dynorphin peptides primar-
ily act at presynaptic κ-opioid receptors to inhibit excitatory
amino acid release from perforant path and mossy fiber ter-
minals and can thereby reduce excitability [134].
Anticonvulsant Neuropeptides as Treatment for Infantile
Spasms
Infantile spasms are a specific type of seizures seen in an
epilepsy syndrome of infancy and childhood known as West
syndrome. The term infantile spasm is also used as a synonym
for this syndrome. The underlying causes may include peri-
natal insults, structural abnormalities, neurocutaneous syn-
dromes, metabolic diseases, CNS infections, or genetic disor-
ders [135].
Adrenocorticotropic Hormone
ACTH, also known as corticotropin, is together with β-
endorphin derived from the proopiomelanocortin (POMC)
precursor. ACTH acts through binding the melanocortin re-
ceptors (MCR). Five receptors (MCR 1–5) have been identi-
fied, however, whether ACTH is an endogenous ligand of all
these receptors has not been determined. Today, ACTH is the
most commonly used first-line treatment for infantile spasms
due to an unknown etiology or due to structural/metabolic
etiology [4].
The stress/corticotropin-releasing hormone (CRH) hypoth-
esis proposes that all the etiologies of infantile spasms share
the common characteristic of being stressful to the immature
brain causing an increase in the release of stress-activated
mediators, especially the neuropeptide CRH in limbic,
seizure-prone brain regions [136, 137]. Animal studies con-
firm that intracerebroventricular infusion of CRH results in
seizures in young rats. These CRH-induced seizures originate
from the amygdala and then spread to the hippocampus [138].
CRH can act through binding two receptors, CRH-R1 and
CRH-R2, which are both present in the amygdala. CRH-R1 is
most likely responsible for mediating the convulsant effects of
CRH in the developing brain, as selective CRH-R1 antago-
nists increase the latency and decrease the duration of CRH-
induced seizures [139]. In addition, elevated CRH and CRH-
R1 expression was found in postmortem brain from children
with generalized seizures, while no significant difference in
the expression of CRH-R2 was observed [140]. Activation of
CRH receptors in the amygdala and hippocampus might lead
to hyperexcitability by suppression of afterhyperpolarisation
and potentiation of glutamatergic neurotransmission [141,
142]. Hence, excess secretion of CRH might trigger seizures.
A drastic decline of CRH receptors, occurring with matura-
tion, would be responsible for the reduction in this peptide-
mediated hyperexcitability later in life [143]. Animal studies
confirm that CRH-induced seizures are considerably less
prominent in adult rats compared to infant rats [144].
ACTH and oral steroids can ameliorate infantile spasms by
reducing the synthesis and release of endogenous CRH [145,
146]. ACTH is produced and secreted by the anterior pituitary
in response to hypothalamic CRH and promotes the release of
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adrenal steroids (primarily cortisol) into the bloodstream. The
effect of ACTH on steroid secretion is mediated by MCR-2.
Steroid hormones have a multitude of effects throughout the
body, among which suppression of the proconvulsant neuro-
peptide CRH. ACTH can also act on melanocortin receptors
(most likely MCR-4) located on CRH-expressing neurons in
the amygdala and, hence, suppress CRH expression indepen-
dently of adrenal steroids [147]. This explains the enhanced
potency of ACTH compared to steroids in the treatment of
infantile spasms. Children with infantile spasms show reduced
ACTH levels in CSF [148–150]. This is in line with the
expected high CRH levels. Chronic activation of CRH recep-
tors leads to their desensitization, which decreases ACTH
release [151]. ACTH is currently one of the recommended
therapies for infantile spasms, but its efficacy is not universal
and prolonged administration can lead to serious side effects
[152]. Agents who either activate melanocortin receptors or
block the seizure-promoting action of CRH could present
therapeutic alternatives.
Thyrotropin-Releasing Hormone
TRH is a tripeptide that is released from the hypothalamus and
stimulates the release of thyroid-stimulating hormone and
prolactin from the anterior pituitary. TRH is also expressed
in other brain regions including the cerebral cortex, hippo-
campus, amygdala, striatum, and brainstem. A single TRH
receptor gene has been found in humans, while two genes
encoding homologous receptors, TRH-R1 and TRH-R2, are
present in rodents. TRH-R1 is the major form in the anterior
pituitary gland, while TRH-R2 is present in other brain sites
[153]. TRH and TRH mRNA are substantially upregulated
over several days after electroconvulsive and amygdala-
kindled seizures, whereas the TRH receptor and receptor
mRNA are downregulated in seizure prone areas such as the
amygdala and hippocampus [154–156].
Clinical studies show that TRH can be used to treat infan-
tile spasms [5–7]. The effectiveness of TRH has been reported
in West syndrome, Lennox–Gastaut syndrome, and early in-
fantile epileptic encephalopathy that were intractable to
ACTH and other conventional anticonvulsants. It was pro-
posed that TRH may act as an antiepileptic through a
kynurenine mechanism, as TRH increases CSF kynurenine
levels in patients with intractable epilepsy and kynurenic acid
acts as an antagonist on the NMDA receptor complex [157].
In the rat hippocampus, it was shown that TRH also increases
GABA release, which may also contribute to its antiepileptic
effects [158]. Further studies are required to elucidate the
exact mechanism of its antiepileptic action. TRH is considered
as a possible new treatment for children with infantile spasms,
as side effects were minimal in the first clinical studies. The
peptide itself is however a poor drug candidate due to its short
plasma half-life (5 min), poor CNS permeability, and
endocrine side effect. Therefore, selective TRH analogs that




β-Endorphin is a neuropeptide that is derived from the same
POMC precursor as ACTH. β-Endorphins are present abun-
dantly in the hypothalamus and pituitary gland and are re-
leased when the body encounters stress or pain. During pain,
they exert an analgesic effect. During stress, they are released
in the limbic system and reduce the extent of anxiety. β-
Endorphin exerts its effect through binding the opioid recep-
tors, with highest affinity for the μ-receptor. μ-Receptors are
located presynaptically and inhibit the release of the inhibitory
neurotransmitter GABA and cause more dopamine to be
released [125]. As for ACTH, the release of β-endorphin is
promoted by CRH. Hence, β-endorphin levels could be influ-
enced in patients with infantile spasms; however, current data
are conflicting. In one study, β-endorphin and ACTH show
decreased levels in the CSF of children with infantile spasms
[148]. In contrast, another study shows normal levels of β-
endorphin and reduced ACTH levels in the CSF of patients
with infantile spasms and thus an increased β-endorphin/
ACTH ratio [160].
β-Endorphin induces nonconvulsive limbic epileptiform
activity when administered intraventricularly to rats, suggest-
ing that β-endorphin plays a role in regulating limbic excit-
ability [161]. Repeated microinjection ofβ-endorphin into the
amygdala or hippocampus leads to the development of gener-
alized convulsions, an effect that could be antagonized by a μ-
receptor specific antagonist [162].
Enkephalins
Leu- and met-enkephalin are both pentapeptides with respec-
tively C-terminal leucine and methionine and are derived from
the proenkephalin precursor. They belong to the family of
endorphins and act through binding the opioid receptors, with
highest selectivity for the δ-opioid receptor. Several studies
report changes in enkephalin levels upon seizures (reviewed
in detail by [2]). In animal models, limbic seizures induce
dramatic increases in enkephalin immunoreactivity in the
hippocampus, most prominently within the mossy fibers
[117]. In fact, a single systemic kainate injection in adult rats
upregulates proenkephalin mRNA and its peptide products in
the hippocampus for at least 1 year [163]. Also in patients with
generalized epilepsy, an increase in enkephalin immunoreac-
tivity was found in the CA regions of the hippocampus [164].
This suggests an important role for this peptide in the
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occurrence of recurrent, unprovoked seizures in TLE. In the
neonatal rat brain, elevated met-enkephalin levels were also
observed immediately after hyperthermia-induced seizures
[165]. Leu-enkephalin levels, however, are significantly lower
in the CSF of patients with FS [166].
There is strong evidence from animal models that enkeph-
alins act as proconvulsive agents. Met-enkephalin was shown
to have an epileptogenic effect in the rat brain. Repeated
microinjection of met-enkephalin into the amygdala led to
the development of generalized convulsions [167]. A δ-
receptor agonist also effectively kindled convulsions when
microinjected into the amygdala or ventral hippocampus
[162]. In addition, a δ-receptor selective agonist was shown
to produce a brief, nonlethal convulsion in mice, similar to the
effect of PTZ [168]. Activation of δ-receptors also increases
the incidence of bicuculline-induced convulsions in mice
[169]. On the other hand, δ-receptor antagonists were shown
to depress PTZ-induced kindling in rats [170, 171]. Enkeph-
alins are known to inhibit spontaneous GABA release from
inhibitory neurons in the hippocampus, resulting in increased
excitability [172].
Tachykinins
Tachykinins are widely distributed throughout the central and
peripheral nervous system, and numerous functions have been
attributed to them. Tachykinins have also been implicated in
epilepsy. In humans, two tachykinin genes have been de-
scribed, TAC 1 and TAC 3. TAC 1 encodes the peptides
neurokinin A, substance P and two N-terminally extended
forms of neurokinin A, neuropeptide K, and neuropeptide γ.
TAC 3 encodes neurokinin B. Substance P acts through the
NK1 receptor and neurokinin A and B act through the NK2
and NK3 receptor, respectively. Seizures alter the concentra-
tions of substance P, neurokinin A, and neurokinin B [118,
173]. Immunoreactivity for substance P and neurokinins sig-
nificantly decreases in the frontal cortex, dorsal hippocampus,
and striatum of rat brains immediately after kainic acid-
induced seizures. One to 3 days after injection of kainic acid,
peptide levels recover, and 10–60 days later, they are signif-
icantly increased in the frontal cortex and the hippocampus.
NK1 is expressed on somatostatin-containing interneurons,
which are significantly decreased in TLE patients and in
several animal models after repetitive seizures [67].
Tachykinins are involved in generating limbic seizures and
in hippocampal-selective neuronal vulnerability. Mice with
disruption of the TAC1 gene show a reduction in duration
and severity of seizures induced by kainic acid or PTZ
resulting in the prevention of both necrosis and apoptosis of
hippocampal neurons [174]. Systemic administration of a
NK1 antagonist reduces kainic acid-induced seizure activity,
supporting a proconvulsive action for substance P [175].
Other studies suggest that substance P contributes to both
the initiation phase and maintenance phase of SSSE [176].
During SSSE, the expression of substance P is enhanced.
Intrahippocampal injection of substance P triggers SSSE,
while injection of NK1 antagonists prevented and stopped
it. The substance P mediated excitation of hippocampal
neurons might be explained by an increase in glutamate
release [176].
Arginine-Vasopressine Peptide
Arginine-vasopressine peptide (AVP) is synthesized in the
supraoptic and paraventricular nuclei of the hypothalamus,
from which AVP-containing neurons project to the posterior
pituitary, amygdala, and septum. Three AVP receptors (V1a,
V1b, and V2) exist in mammals, and, in addition, AVP shows
nanomolar affinity for the oxytocin receptor (OTR). V1a is
widely distributed in peripheral tissues and different areas of
the CNS, including the cerebral cortex, hypothalamus, hippo-
campus, and brainstem. V1b is mostly expressed in the pitu-
itary gland and also in other brain regions and peripheral
tissues. V2 is mainly present in the kidney, but is also present
in the brain, where it was demonstrated in the hippocampus of
newborn rats [177]. AVP acts as an endogenous antipyretic,
attenuating fever by influencing the thermoregulatory neurons
in the anterior and preoptic region of the hypothalamus and in
adjacent septal areas. Although the antipyretic effect of AVP
release during fever is beneficial, excessively high levels of
AVP may be detrimental. There is evidence that increased
levels of AVP released during fever may be involved in the
precipitation of FS [178]. Rats that genetically lack AVP and
rats passively immunized with anti-AVP antiserum show an
increased body temperature threshold for convulsions [179].
High blood levels of AVP in hyperthermic convulsing rats
compared to hyperthermic nonconvulsive rats also support the
hypothesis that AVP may mediate febrile convulsions. AVP
levels in the hypothalamus increase in a rat model of FS
immediately after ultra-red irradiation and significantly de-
crease after convulsions, when body temperature is normal-
ized [74].
The role of AVP is not restricted to febrile convul-
sions. Also in other seizure models, there is evidence
that AVP exerts proconvulsant effects. AVP mRNA
levels are increased following kainic acid-induced sei-
zures [180, 181]. Intraventricular AVP administration
leads to convulsions or abnormal behaviors associated
with epileptic discharges in rats [182, 183]. Subcutane-
ously administered AVP potentiates pilocarpine-induced
seizures [184]. Studies with antagonists for the AVP
receptors V1 and V2 provide further evidence that
AVP has a convulsant activity mediated by V2 receptor
activation. V2 receptor antagonists not only prevent
hyperthermic convulsions but also the status epilepticus
induced by pilocarpine in adult rats [185].
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Pituitary Adenylate Cyclase-Activating Polypeptide
Pituitary adenylate cyclase-activating polypeptide (PACAP)
belongs to the glucagon–secretin–vasoactive intestinal pep-
tide (VIP) family of peptides. PACAP is expressed in various
brain regions where it serves neurotrophic, neuromodulatory,
and neurotransmitting functions. High concentrations are
found in the neocortex, hypothalamus, hippocampus, and
brainstem. PACAP can activate three different subtypes of
receptors which are widely distributed in the CNS: the
PACAP-specific PAC1 receptor and two PACAP/VIP-
indifferent VPAC1 and VPAC2 receptors. PACAP is one of
the main regulators of the neurohypophyseal secretion of AVP
[186]. Systemic administration of PACAP in rats leads to a
decrease in the threshold for the development of FS [187].
This is most likely an indirect effect as PACAP stimulates
AVP neurosecretion and AVP is known to mediate
hyperthermia-induced seizures [179]. However, it has also
been shown that PACAP mRNA is increased in the
paraventricular nucleus of the hypothalamus after kainic
acid-induced seizures in rats [188]. More studies are needed
to investigate the role of PACAP in seizure susceptibility.
Neuropeptides with Less Clear Overall
Anti-/Proconvulsant Effects
Oxytocin
Oxytocin is synthesized in neurons of the supraoptic and
paraventricular nuclei of the hypothalamus. The oxytocin
gene shares considerable homology and a common ancestral
origin with the vasopressin gene. These peptides are also
found in adjacent neurons within the hypothalamic nuclei,
which have similar types of synaptic inputs and respond to
similar physiological stimuli for release. Oxytocin binds to
both the OTR and the vasopressin 1a receptor (V1a).
A case report of a prolonged temporal lobe epileptic seizure
revealed that both vasopressin and oxytocin plasma concen-
trations are elevated during the generalized phase of a seizure
[189]. Also in the rat PTZ model, oxytocin plasma levels are
consistently elevated [190]. Following kainic acid-induced
seizures, both oxytocin and vasopressin mRNA levels in
hypothalamic nuclei are increased [180]. Another study
showed that oxytocin-containing neurons of the paraventricular
nucleus are activated following generalized seizures [191].
On the other hand, in the kindled-seizure model, no changes
in oxytocin expression were found [192], and in the PTZ
model, hypothalamic oxytocin mRNA is significantly reduced
immediately after treatment [193].
Contradictory results have been described concerning the
role of oxytocin in seizures. In 1978, a case report described a
patient that experienced a generalized epileptic convulsion
after intra-amniotic prostaglandin F2 alpha administration
together with intravenous oxytocin infusion [194]. In the
mouse PTZ model, it was also shown that oxytocin has
proconvulsive properties and these are mediated by the V1a
receptor [195]. These effects were seen after a single high dose
of oxytocin (0.5 mg/kg ∼500 nmol/kg). A lower dose of
0.25 mg/kg did not alter seizure susceptibility. In contrast,
lower doses of oxytocin were shown to be anticonvulsive in a
rat model of PTZ-induced seizures. Respectively 40, 80, and
160 nmol/kg oxytocin were administered once daily for five
consecutive days, after which EEGs were recorded. The two
highest doses presented a decreased convulsion scale and less
EEG abnormalities [196]. Also in zebrafish, oxytocin and its
nonmammalian homologue isotocin show anticonvulsive ef-
fects leading to a decreased number of seizures after a PTZ
injection [197]. This suggests that the dose of oxytocin is
crucial and high doses might lead to seizures. OTR null mice
have an increased susceptibility for seizures, a characteristic
that was antagonized by peripherally administered oxytocin.
The latter is probably explained by a possible upregu-
lation of V1a and an interaction of oxytocin with these
receptors. Because hippocampal neurons from OTR null
mice express a lower percentage of GABAergic synap-
ses, it is possible that an imbalance in glutamate–GABA
transmission is responsible for the increased seizure
susceptibility [198].
Melanin-Concentrating Hormone
Melanin-concentrating hormone (MCH) is a neuropeptide
produced primarily in the lateral hypothalamus and zona
incerta. It interacts with two G-protein coupled receptors, the
melanin concentrating hormone 1 and 2 receptor (MCHR1
andMCHR2), of which onlyMCHR1 is expressed in rodents.
MCH neurons project to several brain regions with known
involvement in epileptic seizures. MCHR1 is expressed
throughout the brain with particularly dense localization in
the nucleus accumbens shell, hippocampus, amygdala, locus
coeruleus, and cerebral cortex.
Central MCH administration evokes a strong anticonvul-
sant effect in PTZ-treated rats [199]. Comparisons between
MCHR1-KO and WT mice, however, show that inactivation
of the MCH signaling system decreases susceptibility to sev-
eral types of seizures [200]. The acute anticonvulsant effect of
MCH could be explained by an immediate inhibitory effect on
neuronal firing in certain brain regions, mediated by MCHR1
that couples to Gi. The long-term proconvulsant role for MCH
could be a consequence of alterations in NMDA receptor
expression, as MCH administration has been reported to pos-
itively regulate NMDA receptor expression in the hippocam-
pus. This phenomenon of “effect inversion” where the effects
of acute administration of an agonist or antagonist/inverse
agonist are opposite to those seen with chronic administration
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is well documented for adenosine, which is also involved in
the regulation of seizures [200].
Other Neuropeptides that Show Potential in the Field
of Epilepsy
Nesfatin-1
Nesfatin-1 or NEFA/NUCB2-encoded satiety and fat-
influencing protein is a recently discovered neuropeptide
expressed in several neurons of the forebrain, hindbrain,
brainstem, and spinal cord and is known as a potent anorex-
igenic substance, playing a role in the hypothalamic pathways
regulating food intake and energy homeostasis [201]. The
receptor through which nesfatin-1 exerts its actions is yet to
be identified. Correlations have been found between nesfatin-
1 levels in body fluids and the course of epilepsy. Patients with
primary and secondary generalized seizures show significant-
ly elevated nesfatin-1 levels in plasma and saliva [202]. The
plasma nesfatin-1 level is in the highest range during
5 min after onset of the attack [203]. In addition,
plasma nesfatin-1 level is significantly elevated in rats
with epileptic seizures induced by kainic acid [204].
The mechanism responsible for this increase is not
known. However, nesfatin-1 can be considered as a
promising marker to diagnose patients who have suf-
fered a recent epileptic seizure.
Vasoactive Intestinal Peptide
Vasoactive intestinal peptide (VIP) belongs together with
PACAP to the glucagon–secretin–VIP family of peptides.
VIP can activate two receptors, VPAC1 and VPAC2, in the
CNS. VIP can enhance the electrical activity of neurons in
many brain regions and could therefore play a role in seizure
disorders. This peptide, however, has not been heavily inves-
tigated in this respect. A short-term and transient decrease in
VIP levels was reported after PTZ and kainic acid-induced
seizures in rats [205, 206]. On the other hand, VIP levels were
elevated in serum and CSF of children with seizure disorders
[207]. A significant upregulation of VIP receptors without a
change in pattern and distribution of VIP immunoreactive
neurons was seen in the seizure focus of human hippocampi
removed surgically from patients with medically intractable
TLE [208]. An upregulation of VIP receptors on pyramidal
neurons might point to an increased excitation of these cells
by VIP. If VIP functions as a trophic substance, the increased
VIP receptor level might also protect neurons from excitotoxic
injury. Another hypothesis is that VIP stimulates glycogenol-
ysis to cope with the increased energy demands of hippocam-
pal seizure onset.
Perspectives
Several endogenous peptides act as neuromodulators that can
suppress seizures in the brain. Examples are ACTH, angio-
tensin, CCK, cortistatin, dynorphin, galanin, ghrelin, NPY,
neurotensin, somatostatin, and TRH. Other neuropeptides,
such as AVP, CRH, enkephalins, β-endorphin, PACAP, and
tachykinins, show proconvulsive properties. These neuropep-
tides and their receptors open new avenues towards generating
AEDs.
Neuropeptides are attractable drug targets due to their high
potency, selectivity for their target receptors, and low toxicity
of their metabolites. Despite the growth in understanding the
role of neuropeptides in epilepsy, peptide-based therapeutics
are staying behind. Several things need to be considered when
using neuropeptide-related targets in the treatment of epilepsy.
A major concern is the disruption of the normal physiological
function(s) of the peptides. Other drawbacks of neuropeptides
are their rapid enzymatic degradation and the fact that many
neuropeptides cannot penetrate the blood–brain barrier
(BBB). However, new technologies open opportunities for
CNS focused peptide-drug delivery. Recently, significant
progress has been made in generating subtype-selective, met-
abolically stable, CNS-penetrant analogs of various anticon-
vulsant neuropeptides [122]. For galanin, NPY, and
neurotensin, the combination of acetylation, cationization,
and lipidization was shown to produce an overall improve-
ment on metabolic stability, generating BBB-permeable, sys-
temically active analogs that protect against seizures [124,
209]. Improved delivery systems may further help in
circumventing the BBB. Intranasal delivery of neuropeptide-
loaded biodegradable nanoparticles provides a promising ap-
proach in seizure therapy. Neuropeptides are delivered directly
to specific CNS targets by transport through the olfactory
epithelium. As a proof of concept, it was shown that intranasal
delivery of TRH/analog nanoparticles can significantly atten-
uate seizures in a kindling model [210, 211]. Gene therapy on
candidate neuropeptide genes also shows promising anticon-
vulsive effects in preclinical studies [212]. AAV vectors sup-
port long-term, nontoxic gene expression in the CNS, and
these AAV properties prove particularly applicable to the
treatment of focal epilepsies, especially intractable TLE
[213]. A hybrid AAV vector can selectively cross the seizure
compromised BBB and transduce cells after peripheral,
intravenous administration. Hence, AAV therapeutics for
focal epilepsies may be delivered without any neurosur-
gical interventions [214]. Moreover, multiple genes can
be expressed from the same vector, meaning that it
should be possible to test the synergy of numerous
combinations of anticonvulsant neuropeptides [215]. Ex-
tensive studies on the inhibitory neuropeptides galanin
and NPY have generated enough preclinical evidence of
efficacy to warrant AAV-based clinical trials.
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As neuropeptide expression is significantly altered in spe-
cific epileptic conditions, neuropeptides might also be consid-
ered as biomarkers. Since the treatment of seizures depends on
an accurate diagnosis, making sure that a person has epilepsy
and knowing what kind is a critical first step. There are many
other disorders that can cause changes in behavior and can be
confused with epilepsy. Nesfatin-1 could, e.g., be a candidate
biomarker, as nesfatin-1 levels are significantly elevated in
plasma and saliva of epilepsy patients that experienced a
recent attack [202, 203].
Finally, there is a pressing need for drugs that are truly
antiepileptogenic, i.e., drugs that prevent the process by which
the brain becomes epileptic. To evaluate the potential of
endogenous neuropeptides as disease-modifying drugs more
(pre)clinical studies are needed.
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